Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Serum prostate-specific antigen (PSA) level is the most valuable biomarker in prostate cancer. This study investigates the predictive value of achieving >30% PSA decline at four weeks of first-line androgen signaling inhibitors (ASIs) using a multi-institutional cohort dataset of...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancers (Basel)
Main Authors: Uchimoto, Taizo, Komura, Kazumasa, Fukuokaya, Wataru, Kimura, Takahiro, Takahashi, Kazuhiro, Nishimura, Kazuki, Nakamori, Keita, Fujiwara, Yuya, Matsunaga, Tomohisa, Tsutsumi, Takeshi, Tsujino, Takuya, Maenosono, Ryoichi, Yoshikawa, Yuki, Taniguchi, Kohei, Tanaka, Tomohito, Uehara, Hirofumi, Ibuki, Naokazu, Hirano, Hajime, Nomi, Hayahito, Takahara, Kiyoshi, Inamoto, Teruo, Egawa, Shin, Azuma, Haruhito
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7866532/
https://ncbi.nlm.nih.gov/pubmed/33573172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13030526
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים